With the spread of the coronavirus vaccines developed by Moderna, as well as Pfizer and BioNTech, the world reached several more pandemic milestones this week. the advancement of attempts to examine other experimental recordings; and the approval or approval of coronavirus vaccines in several countries. The welcome news comes as the number of known infections climbs to 83 million worldwide.
The UK announced on Wednesday that it was the Oxford-AstraZeneca Vaccine. The vaccine is cheaper than others – $ 3-4 per dose – and unlike some of its freeze-bound counterparts, it can be kept in a regular refrigerator, making it easier to carry and administer. The vaccine should be given in two doses four weeks apart. However, the UK plans to wait up to 12 weeks for the second shot to release more doses for the first injections. Some early evidence suggests the delay might improve the vaccine’s ability to protect people from Covid-19, although experts have repeatedly suggested that more data is needed.
The state-owned Chinese company Sinopharm announced that one of its experimental vaccines, developed by the Beijing Institute of Biological Products, had an efficacy rate of 79 percent based on an interim analysis of the Phase 3 trials, prompting the Chinese government to give the shot full approval To give. The vaccine was also approved in the United Arab Emirates and Bahrain. The company has not yet released the detailed results of its late-stage clinical trials.
NovavaxThe Maryland-based company announced Monday the start of a late-stage clinical trial that will enroll approximately 30,000 people in the United States and Mexico. Two-thirds of the volunteers in the study will receive the company’s vaccine. The other 10,000 will receive a saline intake as a placebo. Like many other vaccines, Novavax’s vaccine requires two doses. The vaccine can be kept stable in a normal refrigerator.
The World Health Organization gave the Pfizer-BioNTech Vaccine Thursday an emergency seal of approval that was the first to be awarded to a Covid-19 vaccine. Adding it to the organization’s emergency list allows the vaccine to move faster through regulatory approval in countries around the world. The move also enables the vaccine to be distributed through Unicef and the Pan American Health Organization.